Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any sex or gender
- People who have been diagnosed with chronic myelomonocytic leukemia (CMML) according to 2022 medical classification standards
- People whose CMML is rated as intermediate-2 or high-risk using specific scoring tools (CPSS or CPSS-mol), and who are already planned to receive a stem cell transplant from a donor
- People who have a suitable stem cell donor available — the level of genetic matching required depends on whether the donor is a half-matched family member, an unrelated donor, or a fully matched sibling (confirm specific matching details with the trial site)
- People whose overall health and organ function meet specific standards, including a low score on a transplant health assessment tool (HCT-CI score of 2 or lower)
- People whose heart is pumping effectively (at least 50% efficiency) and who do not have uncontrolled heart rhythm problems
- People whose liver and kidney function blood test results fall within acceptable ranges
- People whose blood oxygen level at rest is above 92%
- People whose lung function tests meet minimum levels for two specific measures (confirm details with trial site)
- People who are well enough to carry out basic daily activities (rated 0–2 on a standard health performance scale)
- People who agree not to participate in any other interventional clinical trial during the treatment period
- People who are willing and able to give written consent and follow the study requirements
Who may not be able to join:
- People who have previously had a donor stem cell transplant for CMML that later came back
- People who are unwilling or unable to receive the treatment used in this study
- People with active hepatitis B or C, chronic active hepatitis, or a known HIV infection
- People with an active, uncontrolled infection — including signs such as unstable blood pressure related to infection, worsening infection symptoms, new infection areas visible on scans, or unexplained ongoing fever
- People who have had a stroke or bleeding in the brain within the 6 months before joining
- People who are currently pregnant or breastfeeding
- People who have been diagnosed with another type of cancer within the past 2 years — with some exceptions for certain early-stage or treated cancers (confirm specific exceptions with the trial site)
- People who have any other condition that the trial doctor considers would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yuqian Sun, MD, Peking University People's Hospital
Phone: +86 13717833825
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
One-year relapse-free survival (RFS) after allogeneic hematopoietic stem cell transplantation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.